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Population ageing is often perceived negatively from 
an economic standpoint. Yet, taking a more balanced 
view, it becomes evident that an increasingly older 
population is not necessarily very costly to care for and 
that older people provide significant economic and so-
cietal benefits – particularly if they are healthy and ac-
tive. In this brief article we consider key policy ques-
tions associated with population ageing, bringing to-
gether the latest evidence. We review what is known 
about the health and long-term care costs of older 
people, and consider many of the economic and soci-
etal benefits of healthy ageing. We also explore policy 
options within the health and long-term care sectors, 
as well as other areas beyond the care sector, which 
either minimize avoidable health and long-term care 
costs, support older people so that they can continue 
to contribute meaningfully to society, or otherwise 
contribute to the sustainability of care systems and the 
wider public sector in the context of changing age de-
mographics.
Introduction
By 2050, nearly every country will experience an in-
crease in the share of their population over age 60 due 
to reductions in fertility rates, coupled with declines 
in both infant mortality and premature deaths that 
have enabled longer life expectancies(1). High-income 
countries in particular are seeing sizeable increases in 
the oldest old, those people 80 years and older.
Such population ageing presents both challenges 
and opportunities for societies around the world (2, 3). 
As the share of the population at older ages increases, 
there are concerns over how to respond to greater 
health and long-term care needs and how to cope with 
the possible economic and fiscal implications of hav-
ing a smaller share of people at traditional working 
ages. Many perceive that a changing population age-
structure will have inevitable consequences for house-
holds, public finances and possibly even for economic 
growth and development.
However, evidence suggests that many of the com-
monly considered macro effects of population ageing 
are exaggerated and that there are a range of appropri-
ate policy responses that can help avoid the worst out-
comes commonly associated with population ageing. 
First, while ageing will bring higher needs for and 
costs of care, population ageing is not and will not be-
come a primary driver of health expenditure patterns. 
The additional demands on the health system coming 
from a larger older population can in part be moder-
ated with better choices and configurations in health 
and social care. Likewise, although population ageing 
will lead to changes in economic behaviours (and in 
turn the ability to generate public sector revenues 
through taxations), there are a number of strategies 
that can mitigate the effects on public finances. Lastly, 
the evidence suggests that while many older people 
leave the formal labour market, older people can pro-
vide significant economic and societal benefits – par-
ticularly if they are healthy and active –through both 
paid and unpaid work, including caring for other older 
people.
To manage the challenges and to take advantage of 
the opportunities afforded by population ageing, poli-
cy makers must act across a range of domains such as, 
on work and employment, on income security, on pro-
moting healthier lifestyles and on developing new and 
more efficient models of care. This short article aims to 
provide a balanced summary of the evidence, drawing 
on some of the work from the European Observatory 
on Health Systems and Policies programme on the 
Economics of Healthy & Active Ageing.
What are the implications  
of population ageing for health  
and long-term care expenditures?
In general, on a per person basis, health and long-
term care needs and expenditures increase with age. 
This contributes to concerns that an ageing population 
will rapidly accelerate health expenditure growth rates. 
It should be noted, however, that there are important 
differences across countries in how much is spent on 
health per person for older people. For example, ac-
cording to health care spending by age data collected 
for countries in the European Union (EU) by the 
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Working Group on Ageing Populations and Sustain-
ability (AWG) of the European Commission, in 2015, 
health care spending for the average 80-year-old in 
Hungary were almost 16 times higher than spending 
on the average 20-year-old in Hungary, but this differ-
ence was only 2.7-fold in Cyprus(4).
Despite this typical pattern of higher health care 
spending on older people, available data show that 
population ageing has in fact a relatively modest effect 
on health care expenditure trends compared to other 
important historical drivers of health expenditure 
growth, such as prices or technological innovation. 
Changes in population age structure alone are expect-
ed to add less than one additional percentage point to 
the average annual per person health care expenditure 
growth rates between 2010 and 2060 in the average EU 
country (Figure 1). Population ageing is simply too 
gradual a process to rapidly accelerate health care ex-
penditure growth.
Additionally, much of the evidence suggests that 
calendar age itself is not the primary reason for higher 
health care spending associated with older ages any-
ways. Rather, related factors such as proximity to death 
and poor health are more important determinants of 
health spending (6–8). Poor health and disability are 
important drivers of health care expenditure trends at 
all ages, not just among older people. Likewise, al-
though health care spending increases rapidly in the 
final months of life, there is research showing that be-
ginning at some age, the older people are when they 
die, the lower their health spending is near to the end 
of their life(7) (9). This is likely due to lower use of re-
source-intensive interventions in older ages (although 
it may also reflect discriminatory practices and age-
ism). Therefore, as longevity increases, it is possible 
that the health care costs of older people relative to 
younger people will actually fall, especially if older 
people live in better health, thereby reducing the oth-
erwise expected effects of population ageing on total 
health care expenditure growth in the future.
It is worth noting that the presence of a formal or 
informal long-term care system may be another rea-
son behind declining health care expenditures among 
the oldest old, as costs are shifted outside of the tradi-
tional health care sector into other settings. Where 
formal long-term care is available, its costs are expect-
ed to increase rapidly as a result of population ageing. 
However, this growth in spending on long-term care is 
coming from a low baseline in most countries. The 
majority of Organisation for Economic Co-operation 
and Development (OECD) countries with data avail-
able currently spend less than 2% of gross domestic 
product (GDP) on long-term care, which means that 
even large increases in spending are unlikely to con-
sume a large share of resources.
How will population ageing affect  
the ability to generate revenues  
for health and the public sector more broadly?
There is a common belief that older people are ‘de-
pendent’ on the financial support of society, particu-
larly younger people in paid employment who fund 
the public sector through their taxes. This misconcep-
tion is reinforced by traditional metrics like the old-
age support ratios, which assume that all people over a 
certain age threshold (usually age 65) depend on the 
support of all adults below it. However, not all people 
over 65 retire and/or are dependent and many people 
stop paid work below the age of 65. Alternative ap-
proaches to measuring support ratios attempt either to 
more properly account for changes in population 
health and disability (though few studies measure care 
or functional dependency states), or for changes in the 
Figure 1. Additional growth in per 
person health expenditure 
attributable to population ageing, 
European Union average, 2015–2060
Source: (5)
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number of consumers and producers in the popula-
tion(10) (11). These refined indicators suggest that 
population ageing will create significantly fewer de-
pendency related challenges than anticipated. For ex-
ample, estimates from the United Kingdom suggest 
that while the traditional old-age support ratio will 
increase from 27% (2005–10) to 41% (2045–50), the 
share of the adult population with disability will stay 
unchanged at 10% during the same period.
It is important to move even further beyond old-age 
support ratios to have a clearer sense of how popula-
tion ageing affects the ability to generate public sector 
revenues. In European countries, the main sources of 
public sector revenues are income taxes, goods and 
services taxes, property taxes, and social contribu-
tions. As populations age, countries will likely experi-
ence changes in the ability to generate revenues from 
each of these sources. Older people on average con-
tribute less to public-sector revenues than working-
age people as they leave the formal labour market, al-
though they do still contribute significant amounts 
through taxation. For example, older people who are 
not in paid work continue to pay goods and services 
taxes as well as taxes on non-labour income and assets 
(e.g. property). These may still be significant shares of 
public sector revenues: tax revenues generated from 
purely non-income sources (i.e. non-labour, but also 
capital gains which may be earned by older people) 
comprise around 30% to upwards of 50% of tax reve-
nues in OECD countries (12).
Simulations allow us to quantify precisely how pop-
ulation ageing affects the ability to generate public sec-
tor revenues from different revenue sources. Using 
population data from Japan, where a large share of the 
population is already at older ages and increasingly ex-
iting the formal labour market over time, estimates 
suggest that relying on social contributions primarily 
generated from the labour market to raise public sec-
tor revenues and pay for health and other services re-
sults in declining revenues per person over the coming 
decades (13). Other forms of taxation, such as taxes 
on goods and services or income taxes appear less sus-
ceptible to population ageing, while property taxes 
may even increase as the age-structure of the popula-
tion shifts (Figure 2).
Possible policy options to address declines in la-
bour-related social contributions due to population 
ageing include: increasing the number of contributors; 
increasing the contribution rate on social contribu-
tions; and diversifying the mix of financing sources. 
However, for countries that depend heavily on the la-
bour market to finance health, none of these policy op-
tions on its own is likely to make up for the shortfall in 
revenues due to population ageing according to simu-
lations. Declining social contribution revenues can be 
expected even if the revenue base were broadened or if 
contribution rates were raised equally across all age 
groups. Diversifying the mix of revenue sources in fa-
vour of sources that are less affected by ageing may be 
an appropriate solution. However, countries will likely 
still need to reprioritize their current public-sector 
budgets and allocate more resources to health, or in-
crease tax rates on alternative revenue generation 
sources in order to maintain sufficient and stable rev-
enues for health(13).
This type of analysis demonstrates that sustainable 
revenue generation is possible in the context of popu-
lation ageing, but it underscores the importance of 
moving away from financing the health system and 
public sector more broadly through labour-related 
contributions and premiums and instead relying more 
on general non-earmarked taxation as the population 
ages.
Figure 2. How will per person tax 
and social contributions be 
affected by population ageing? 
(Japan example, index 2015 = 100)
Source: (13)
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What are the implications  
of population ageing for paid  
and unpaid work?
While population ageing will likely lead to changes 
in economic behaviours that have consequences for 
public sector revenues, as discussed above, there re-
mains great scope for older people to contribute mean-
ingfully to society and the economy through both paid 
and unpaid work, particularly if they are healthy and 
able to remain active. Although many people leave 
paid employment in their 60s, others do remain in 
paid work(14). Comparatively older workers have his-
torically produced less economic output than younger 
workers, however this may reflect labour market reali-
ties that are no longer valid, such as requiring the ca-
pacity to carry out physically demanding work. There 
are important differences in how productivity changes 
over the life course by type of occupation; for example, 
jobs requiring less physical exertion may benefit from 
additional years of experience where skills continu-
ously improve with age, and more experience often 
improves the quality of the work. Even if older workers 
are slightly less productive (which may be due to dis-
criminatory practices and ageism, such as poorer ac-
cess to training at older ages), they are still able to 
make a positive economic contribution compared to if 
they are not working at all. In fact, empirical evidence 
suggests that on average many people have consider-
able health capacity to continue to engage in the for-
mal labour market at older ages (15, 16).
Many older people produce unrecognized economic 
and societal value through unpaid work. One of the 
most relevant forms of unpaid work is informal care-
giving. If national statistics accounted for informal 
carers (adjusted for full-time equivalency (FTE)) it 
would have a substantial effect on measured employ-
ment rates of older people. For example, among the 
population aged 55+ in Portugal, including informal 
carers would have increased the employment rate by 
nearly 13 percentage points in 2014 (Figure 3). Meth-
ods to monetize the value of unpaid informal caregiv-
ing also demonstrate its considerable economic value, 
with one study in Spain suggesting the value of infor-
mal caregiving being in excess of 2% of GDP (17). 
However, informal care, especially if it is very demand-
ing on those providing it is not without cost, and the 
availability of informal caregiving depends in part on 
the supports given to carers and the availability of 
complementary formal care.
Provision of informal care by older people also has 
knock-on effects on formal employment rates, for ex-
ample, of adult children. If older people are able to 
provide informal care to dependent older people or 
care for grandchildren, adult children who would oth-
erwise be providing care may be able to work in paid 
employment. This is an important channel through 
which older people contribute to the economy that re-
mains invisible in national statistics.
The policy options:  
how can decision-makers respond  
to population ageing?
The health care and long-term care costs of older 
people, as well as the ability of older people to contrib-
ute meaningfully to society and the economy are de-
Figure 3. Participation in paid employment and full time equivalent (FTE) informal 
caregiving among the 55+, selected European countries
Source: Author’s calculation based on ESS, 2014 [31].
Notes: Sorted by size of workforce in informal caregiving.
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pendent on a number of factors, many of which are 
amenable to policy intervention. Undoubtedly, health 
and functional ability are of utmost importance. This 
is because of their intrinsic value as well as their indi-
rect effects on the economy via their impacts on reduc-
ing care costs and promoting the ability of older people 
to contribute. Healthy older people require less inten-
sive and expensive care; they are able to engage in paid 
or unpaid work if they choose to do so; and they ac-
cumulate greater asset wealth compared to unhealthy 
people. Policy-makers can employ a range of policies 
and strategies in order to control costs of care and en-
hance economic and societal contributions of older 
people, ensuring that population ageing does not lead 
to undue economic pressures. Examples of such inter-
ventions, both indirect (via improvements in health 
and functional ability) and direct, are summarized 
below.
Policies to promote healthy and active ageing
The types of interventions that support health and 
activity at older ages include those that delay the onset 
and progression of disease, as well as those that pre-
vent or delay care dependency. Importantly, policies 
which encourage behavioural changes can have sig-
nificant health effects even if those changes do not 
occur until older ages. For example, there is good evi-
dence that those who quit smoking at age 65 live lon-
ger than those who continue to smoke. To prevent de-
pendency, a key focus should be on preventing cogni-
tive decline, where there is some evidence that taking a 
multidomain approach can improve or maintain func-
tionality. Other interventions to prevent or reduce 
frailty, such as resistance training or promoting physi-
cal activity at older ages, can also be effective.
Policies to promote cost-effective health  
and long-term care interventions
Technological advancements, such as telemedicine, 
as well as assistive technologies, such as digital memo-
ry aids or automated medication dispensers, can be ef-
fective ways to provide care using relatively low re-
source levels. There has also been widespread interest 
in integration of health and long-term care and other 
models of care delivery to help control care costs, par-
ticularly given the complex care needs of older popula-
tions. There are many varied examples of delivering 
coordinated or integrated health and long-term care. 
There is also good evidence that supporting better 
treatment and care choices near the end of life can re-
duce the use of unnecessary treatments and tests, 
lower costs, improve the experiences of patients and 
carers and even, in some cases, contribute to longer 
survival.
Policies to support acceptable, equitable  
and efficient funding and income transfers
Given likely reductions in the share of the popula-
tion in paid work as a result of population ageing, 
health and long-term care financing systems may need 
to diversify their sources of revenue if they are to con-
tinue to generate sufficient, stable resources. For ex-
ample, health and long-term care financing systems 
that are heavily reliant on payroll contributions may 
need to be redesigned to fill the financing gap from 
general revenues or private sources.
Increasing the reliance on locally raised taxes or, 
conversely, centrally raised taxes is one focus of ongo-
ing debate and reforms, with countries moving in dif-
ferent directions. The use of hypothecation (or ear-
marking) of payroll or ‘sin’ taxes has been seen by 
some as a potential source of funding. However, many 
argue that this introduces unwelcome budgetary con-
trols and that spending is ultimately determined by 
revenue generated rather than based on changing 
needs and demand. Earmarked funding sources are 
also likely to be susceptible to economic fluctuations, 
resulting in unstable revenue streams. Similar argu-
ments have been made against the introduction of 
mandatory long-term care insurance arrangements, 
such as those seen in Germany, Japan and Korea. 
Overall, acceptability of higher taxes and transfers var-
ies between countries and can depend in part on the 
transparency of the process and the perceived fairness 
of the rules.
Policies to support paid and unpaid work
While there is widespread interest in keeping people 
in paid work for longer, raising pension ages alone 
may simply divert some older people into other state 
support for unemployed people or people with dis-
abilities if they are not healthy enough to work pro-
ductively. Health systems can usefully help to keep 
older people healthy and able to remain in the work-
force. There is also growing recognition that workplace 
health promotion interventions, such as screening ac-
tivities to identify potential health risks and lifestyle 
management activities to improve health and health 
behaviours, can keep older workers healthy and pro-
ductive. Adapting work practices to accommodate 
older workers’ needs and circumstances can also help 
older people to remain in work. Good evidence shows 
that flexible working practices, such as flexitime, part-
time working, job-sharing and working from home, 
can help older people, particularly those with health 
issues or caring responsibilities, to remain in employ-
ment for longer and can result in healthier lives over-
all. Changes to the physical work environment can 
also support older workers to remain in employment, 
while contributing to improvements in productivity.
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On the unpaid work side, strategies that support in-
formal carers through training or by providing cash 
for care have been shown to reduce carers’ stress and 
may also improve the quality of care. However, it is im-
portant to acknowledge that cash-for-care benefits can 
act as a disincentive to participating in formal employ-
ment. Much emphasis has been placed on implement-
ing reforms to enable carers to combine unpaid care 
with paid employment, including the introduction of 
paid or unpaid leave and flexible working arrange-
ments.
Conclusion
Policy-makers require high-quality information to 
make informed decisions and develop policies with re-
spect to older people. This overview of evidence on 
some of the costs and benefits associated with popula-
tion ageing suggests that older people are likely to be 
less costly to societies than often perceived, at least in 
terms of health and long-term care. Older people also 
provide benefits that are frequently not quantified, 
such as in the form of informal caregiving, while oth-
ers remain in paid work at older ages, particularly if 
they are healthy enough and choose to do so.
There are many benefits from investing in the health 
of older people, not least for the sake of economic 
growth and sustainable public finances. Any questions 
regarding the costs of interventions to support the 
health and activity of older people should take into ac-
count the potential benefits not only from an econom-
ic perspective, but also in terms of improving quality 
of life and experiences in older age. As has been de-
scribed above, these sorts of benefits are often not 
properly taken into account.
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K-II
Geroprotectors: Time to Change 
the Way We Take Care of Older 
People?
Ilaria Bellantuono
Academic Unit of Bone Biology The University of Sheffield,  
The Medical School Sheffield, United Kingdom
Human life expectancy has been increasing steadily 
over the last century but this has resulted in an increas-
ing incidence of age-related chronic diseases. Patients 
often present with more than one disease at the same 
time (multimorbidity) and develop frailty. Multimor-
bidity and frailty have complex medical needs and are 
strongly associated with disability and hospitalization. 
However, current treatments are suboptimal with 
problems of polypharmacy due to the fact that each 
disease is treated individually.
Geroprotectors target fundamental mechanisms of 
ageing common to multiple age-related diseases and 
shows promise in delaying the onset of multimorbidity 
in animal models. I will present preclinical data on a 
new geroprotector, Zoledronate (1), together with the 
recommendations from the European network Mouse-
AGE and Healthy Lifespan Institute thinking on the 
steps required to ensure these new interventions are 
translated from the bench to the bedside
R e f e R e n C e s
1. https://biorxiv.org/cgi/content/short/2020.04.09.033498v1
K-III
Importance of Sleep  
for Healthy Ageing – Impact  
of Sleep-Disordered Breathing
Zoran Đogaš
Dean, University of Split School of Medicine
Head, Department of Neuroscience
Director, Sleep Medicine Center
Abstract
Sleep Medicine is growing multidisciplinary field 
within the biomedicine and health. According to the 
International Classification of Sleep Disorders 3 
(ICSD-3), there are about 80 sleep disorders, divided 
into 6 different clinical divisions: insomnia, sleep-re-
lated breathing disorders, central disorders of hyper-
somnolence, circadian rhythm sleep–wake disorders, 
parasomnia, sleep-related movement disorders, as 
well as “other sleep disorders”. Some sleep disorders 
are strongly associated with specific age and they ap-
pear almost exclusively in childhood or in the elderly, 
but most sleep disorders may appear in all age groups. 
However, the prevalence is significantly positively as-
sociated with ageing. Also, there is a significant nega-
tive correlation of sleep duration and sleep quality 
with age, but the impact of poor sleep quality and sleep 
disorders on health, healthy ageing and quality of life 
is not recognized enough, and the public awareness is 
not at the satisfactory level. It is important to state that 
general statements about sleep architecture and sleep 
stages proportions in the total sleep time presented in 
the literature can only be made regarding sleep in the 
normal young adult without sleep complaints who is 
living on a conventional sleep-wake schedule. One of 
the most notable findings regarding sleep in the elder-
ly is the profound increase in inter-individual variabil-
ity, which thus precludes generalizations such as those 
made for young adults.
The most prevalent sleep disorders of today, such as 
insomnia or sleep-related breathing disorders are 
strongly positively associated with age and make one 
of the most important risk factors for diminished qual-
ity of life, as well as increased morbidity and mortality 
of the most prevalent diseases in general population, 
such as cardiovascular and glucose metabolism disor-
ders, but also cancer, which has been published in 
many recent studies. Also, cognitive and psychomotor 
impairments are facilitated in the elderly in the pres-
ence of sleep disorders.
Increasing public awareness, improving and ex-
panding diagnostic and treatment capacities for sleep 
disorders, as well as education of sleep medicine ex-
perts, which was recently developed in the Republic of 
Croatia according to European guidelines, are the pri-
mary goals of up-to-date sleep medicine, one of the 
most prosperous medical discipline, which is going to 
be even more important in the future due to increased 
longevity in general population and strong links of 
sleep medicine and ageing.
sleep
There are many definitions of sleep. According to a 
simple behavioral definition, sleep is a reversible be-
havioral state of perceptual disengagement from and 
relative unresponsiveness to the environment. It is also 
true that sleep is a complex amalgam of physiologic 
and behavioral processes. Sleep is typically (but not 
necessarily) accompanied by postural recumbence, 
behavioral quiescence, closed eyes, and all the other 
indicators that one commonly associates with sleeping 
(Carskadon and Dement, 2011). We spend nearly one-
third of our lives asleep, and many mammals, includ-
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ing small laboratory rodents, spend half or more of 
their existence in this state.
The sleep-wake cycle is regulated by two separate 
biological mechanisms, which interact together and 
balance each other. This model is often referred to as 
the two-process model of sleep-wake regulation com-
posed of the Process C that reflects the circadian 
rhythm, and the Process S that reflects the sleep-wake 
homeostasis (Borbély, 1982).
There are two distinct states of sleep, defined on the 
basis of several physiologic parameters. Rapid eye 
movement (REM) and non-REM (NREM) sleep exist 
in most mammals studied. These states are both differ-
ent from wakefulness and distinct from one another 
(Dogas et al., 2014). However, differentiating sleep (or 
sleep stages) from quiet wakefulness is hardly possible 
at the behavioral level. NREM sleep, formerly sub-
divided into four stages according to standard Recht-
schaffen & Kales (R&K) sleep scoring rules (Rechts-
chaffen and Kales, 1968), is currently distinguished 
into three stages according to the American Academy 
of Sleep Medicine (AASM) scoring rules (Iber et al., 
2007; Berry et al., 2014). Those stages are mostly de-
fined based on the electroencephalogram (EEG). The 
EEG pattern in NREM sleep is commonly described as 
synchronous, with characteristic waveforms such as 
sleep spindles, K-complexes, and high-voltage slow 
waves. NREM stages (stages 1, 2, 3, and 4 according to 
R&K, and stages 1, 2, 3 according to AASM, stage 3 
according to AASM being composed of stages 3 and 4 
according to R&K) represent a depth-of-sleep contin-
uum, where the arousal threshold is generally lowest 
in stage 1 and highest in stage 3 (or 4) sleep. Classical 
studies showed that the sound intensity needed to 
awake a subject is positively correlated with the depth 
of sleep. That is, during deep sleep characterized by the 
slow wave activity as seen in the EEG (hence the name 
“slow wave sleep”), sound intensity had to be greatest to 
lead to awakening. In traditional perspective, NREM 
sleep was usually associated with reduced mental 
 activity. However, recent studies showed it is not the 
case, as for instance there are strong associations 
 between NREM sleep and memory consolidation 
 processes.
Importantly, general statements about sleep stages 
proportions in the total sleep time presented in the 
 literature can only be made regarding sleep in the 
 normal young adult without sleep complaints who is 
living on a conventional sleep-wake schedule. One 
of the most notable findings regarding sleep in the 
 elderly is the profound increase in inter-individual 
variability, which thus precludes generalizations such 
as those made for young adults (Carskadon and De-
ment, 2011).
Chronotypes and sleep
In humans, the most obvious variation in behavior 
organization, during the 24-hour day, can be seen in 
their preferred timing of sleep and wakefulness. Total 
amount and the timing of sleep are determined by sev-
eral factors, including environmental factors, endoge-
nous circadian rhythms and time awake. Human pref-
erences in the timing of sleep and wake are called 
“chronotypes” and are at least partly based on genetics. 
Human chronotypes can be easily investigated using 
convenient self reported questionnaires, such as 
Horne-Ostberg morningness-eveningness question-
naire (Horne and Ostberg, 1976), and Munich Chrono 
Type Questionnaire, that differentiate timing of the 
daily activities during workdays versus free days 
(Roenneberg et al., 2007). Chronotypes (morning-
ness–eveningness) are one of the most common inter-
individual differences in circadian rhythmicity. As 
such, chronotype represents a phenotypic aspect of the 
circadian rhythmicity. Morning-type and evening-
type persons differ in endogenous circadian phase of 
their biological clocks (Roenneberg et al., 2007). 
Moreover, it is well known that diurnal preferences 
(morningness–eveningness) are influenced by person’s 
gender, showing a greater shift toward morningness in 
women than in men. They are driven by reproductive 
hormones and thus endogenously generated. Sex dif-
ferences in human chronotypes disappear at approxi-
mately age of 50 (Roenneberg et al., 2007).
Diurnal preferences are associated with age, as well. 
Although thought to be primarily a genetic trait, it is 
well established that chronotype is not constant 
throughout the adult lifespan. During the childhood, 
children are more morning-types, while during the 
adolescence change in chronotype occurs, shifting 
adolescents towards eveningness-types. Also, it has 
been found in cross-sectional studies that chronotype 
changes towards a morning-type orientation with ad-
vancing age (Monk and Buysse, 2014). The biological 
foundation of this has been confirmed by laboratory 
studies showing that older adults (seniors) have circa-
dian rhythms, which phase at an earlier clock time 
(usually by 1–2 h) than those of younger adults (Monk 
and Buysse, 2014).
sleep and age
Sleep is an important component for health and 
wellness across the lifespan. However, older adults do 
not sleep as well as younger adults. Why? What altera-
tions in sleep quantity and quality occur as we age, and 
are there functional consequences? What are the un-
derlying neural mechanisms that explain age-related 
sleep disruption? There are well-known changes in 
human sleep quantity and quality in cognitively nor-
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mal older adults and the functional consequences of 
age-related sleep disruptions. However, there is a still-
debated question: do older adults simply need less 
sleep, or rather, are they unable to generate the sleep 
that they still need? (Mander et al., 2017).
Sleep disturbances are a common presenting symp-
tom of older-age adults to their physicians. There are 
normal changes in sleep pattern with ageing and pri-
mary sleep disorders in the elderly, but behavioral fac-
tors and primary psychiatric disorders affecting sleep 
in this population are numerous.
normal age-related changes  
to sleep-wake physiology
Physicians addressing sleep complaints in older 
adults are commonly asked about how much sleep is 
enough. The National Sleep Foundation recommends 
7–8 hours of sleep for adults aged 65 and older. This 
recommendation is supported by evidence that older 
adults sleeping anywhere from 6–9 hours have better 
cognition, mental and physical health, and quality of 
life compared to older adults with shorter or longer 
sleep durations. Thus, the need for sleep is not reduced 
in older adults, but the ability to get the required sleep 
may be decreased due to normal changes in sleep ar-
chitecture through the lifespan. Age-related changes in 
sleep physiology have been well-documented using 
polysomnography. Most age-dependent changes in 
sleep parameters occur by age 60 years, with the excep-
tion of sleep efficiency. Sleep efficiency (percentage of 
time spent asleep while in bed), on the other hand, 
continues to show an age-dependent decline beyond 
age 90 years. Older adults also have a decline in total 
sleep time, with corresponding decreases in the per-
centage of time in slow wave sleep (SWS or N3) and 
rapid eye movement (REM) sleep. SWS and REM sleep 
are thought to promote metabolic and cognitive recov-
ery, and to enhance learning and memory, respective-
ly. Older adults also have an increase in time awake 
after sleep onset (WASO). While the number of arous-
als from sleep increase in healthy older adults, evi-
dence suggests they do not have greater difficulty fall-
ing back to sleep. There is an increase in sleep latency 
(the time it takes to fall asleep) up to age 60, with no 
clear age effect beyond that point (Monk, 2005).
Circadian rhythm in elderly
Circadian rhythms also change over the lifespan. 
These rhythms are 24-hour intrinsic physiological cy-
cles that are involved in control of sleep-wake and 
many other physiologic processes (e.g. blood pressure, 
bone remodeling, release of certain hormones). Age-
ing is associated with a phase advance, resulting in an 
earlier onset of sleepiness in the evening and earlier 
morning awakening. Daytime wakefulness is affected 
by phase advance, with older adults being more alert 
in the morning and more somnolent in the evening. 
Studies conducted in different age groups revealed that 
adolescents and elderly population are two popula-
tions predominantly at the risk of circadian rhythms 
disorders. Adolescents go to bed considerably later in 
the evening. This is mostly pronounced during work-
ing days and associated with sleep rebound, character-
ized by extended time spent in bed on weekends. 
Changes in circadian rhythm associated with advanced 
age include a tendency to sleep earlier and shift toward 
morning type, with an increased number of naps dur-
ing daytime (Park et al., 2002). While napping is com-
mon in older adults, results with regard to the benefit 
or harm of this practice are mixed. Some studies show 
beneficial and potentially protective effects of napping 
in later life, while others show it to be a risk factor for 
morbidity and mortality. There is some evidence to 
suggest that naps are protective for mortality if night-
time sleep duration is short, but are associated with 
increased mortality risk if nighttime sleep duration is 
longer than nine hours.
Changes in circadian rhythms are associated with a 
decline in sleep quality due to increased sleep latency 
and more pronounced sleep fragmentation during the 
night, emphasizing weakened and fragmented circa-
dian rhythms during ageing (Huang et al., Bliwise et 
al., 2005).
sleep, Ageing and Gender
Though reliable macro and micro sleep differences 
exist between younger and older adults, not all older 
adults suffer the same degree of sleep disruption. In-
stead, there is large inter-individual variability. This 
means that age per se is not the sole determinant of 
sleep disruption in later life. Rather, factors that inter-
act with the aging process must confer vulnerability or 
resilience to age-associated declines in sleep quantity 
and quality.
In the context of older age, one such interacting fac-
tor is gender. Men experience far greater relative dis-
ruption and impairment in NREM sleep than women 
later in life. In a study comparing over 2,500 older 
adults between the ages of 37 and 92 (Redline et al., 
2004), increasing age was reliably associated with the 
same features described above: decreased slow wave 
sleep time, reduced sleep efficiency, increased NREM 
stage 1 sleep time, increased number of arousals, and 
modest decreases in REM sleep time. However, when 
stratified by gender, differences emerged. Men over the 
age of 70 demonstrated a highly significant 50% reduc-
tion in slow wave sleep, relative to men under the age 
of 55, together with a concomitant increase in lighter 
NREM stages 1 and 2. In contrast, women showed no 
such significant decline in slow wave sleep or increase 
in lighter NREM sleep time relative to their younger 
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gender group. Compared between genders, men over 
the age of 70 had more than a 3-fold deficit in slow 
wave sleep amount compared with age-matched 
women. Meta-analyses have replicated this gender-
specific difference in slow wave sleep in older age 
(Ohayon et al., 2004). Interestingly, the moderate re-
duction in REM sleep time in the oldest participants 
(>70 years old) was common to both males and fe-
males, suggesting a gender-independent deterioration 
of this sleep stage.
Gender also impacts age-associated changes in slow 
wave sleep homeostasis. Older adult men demonstrate 
significantly less homeostatic slow wave sleep rebound 
during recovery sleep following sleep deprivation than 
equivalent-age older women. As with the comparison 
of basic sleep stages, both elderly men and women 
show similar homeostatic rebounds in REM sleep dur-
ing post-deprivation recovery nights (Reynolds et al., 
1986). Therefore, gender-dependent and gender–inde-
pendent effects emerge in older age, further suggesting 
a model in which some homeostatic mechanisms of 
sleep remain equivalent and somewhat intact in cogni-
tively normal older adult men and women, such as 
REM sleep, while others show strong gender-depen-
dent differences, such as slow wave sleep.
Despite gender-specific changes in NREM sleep 
quantity and quality being more severe in men, a para-
doxical and, as yet unexplained, finding is that women 
are more likely to suffer subjective complaints of poor 
sleep as they get older, relative to older men (Ohayon 
et al., 2004). Whether this is due to report bias on the 
basis of gender, or is explained by an underlying phys-
iological mechanism, remains unclear.
sleep medicine and ageing
Sleep Medicine is growing multidisciplinary field 
within the biomedicine and health. According to the 
International Classification of Sleep Disorders 3 
(ICSD-3), there are about 80 sleep disorders, divided 
into 6 different clinical divisions: insomnia, sleep-re-
lated breathing disorders, central disorders of hyper-
somnolence, circadian rhythm sleep–wake disorders, 
parasomnia, sleep-related movement disorders, as 
well as “other sleep disorders”. Some sleep disorders 
are strongly associated with specific age and they ap-
pear almost exclusively in childhood or in the elderly, 
but most sleep disorders may appear in all age groups. 
However, the prevalence is significantly positively as-
sociated with ageing. Also, there is a significant nega-
tive correlation of sleep duration and sleep quality 
with age, but the impact of poor sleep quality and sleep 
disorders on health, healthy ageing and quality of life 
is not recognized enough, and the public awareness is 
not at the satisfactory level.
sleep disorders in elderly
The number of people in Croatia, as well as in the 
United States who are 65 years or older is steadily in-
creasing. In Croatia, according to the State Depart-
ment for Statistics and the Teaching Department for 
Public Health „Dr. Andrija Štampar“, in 2011 there 
(A) Prototypical sleep stage architecture across a 9 hr sleep period in a 
younger adult (top) and an older adult (bottom), using classic sleep stag-
ing criteria (Rechtschaffen and Kales, 1968). Relative to younger adults, 
older adults demonstrate: longer sleep latency, a greater number of tran-
sitions to lighter stages of sleep and wakefulness, more time spent awake 
after sleep onset, more fragmented sleep, and less time in slow wave 
sleep, especially within the early sleep cycles.
(B) Upper: Representative topographical head plots of EEG-quantified dif-
ferences between younger and older adults in slow wave activity (left 
upper) and density (right upper). A similar sleep spindle density for fast 
sleep spindles (13.5–15 Hz; bottom left) and slow sleep spindles (12–13.5 
Hz; bottom right) is shown in the bottom image. The hotter colors repre-
sent higher values. The center rainbow topoplots in each image represent 
the subtracted difference between younger and older adults, with darker 
blue representing larger deficits in older relative to younger adults. For 
both slow waves and sleep spindles, older adults demonstrate the largest 
regional oscillation impairments over frontal EEG derivations (From Man-
der et al., 2017; the data are adapted from previous reports Mander et al., 2013, 
2014, 2015, 2016b).
Figure 1. Schematic of Age-Related Changes in Sleep 
Architecture and NREM Sleep Oscillations
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were about 17,7% people at 65 years or older and this 
proportion increased in 2016 to 19,41%.
In the US, proportion of this population is expected 
to double over the next 25 years to about 72 million. By 
2030, roughly 1 in 5 people in this country will be over 
the age of 65.
Sleep complaints are common among older adults, 
and as this segment of the population grows, the prev-
alence of sleep disturbances will also increase. How-
ever, sleep problems are not an inherent part of the 
ageing process (Miner and Kryger, 2017).
There are changes to sleep architecture over the 
lifespan that are not, in themselves, pathologic, but can 
be viewed as making older adults more vulnerable to 
sleep disturbances. It is the consequences of ageing, in 
the form of medical and psychiatric comorbidity, 
medication and substance use, psychosocial factors, 
and primary sleep disorders that put older adults at 
risk for sleep disturbance. The increasing prevalence of 
multimorbidity (i.e., having at least 2 concurrent dis-
eases in the same individual) among older adults 
means that sleep disorders might arise from multiple 
different domains. Thus, sleep disturbance in this age 
group should be considered a multifactorial geriatric 
health condition (previously referred to as a geriatric 
syndrome), (Miner and Kryger, 2017) requiring con-
sideration of multiple risk factors and a comprehen-
sive treatment approach.
In general, changes to sleep architecture with nor-
mal ageing include decreases in total sleep time, sleep 
efficiency, slow wave sleep, and REM sleep, and an in-
crease in wake after sleep onset. Although sleep distur-
bance is common with ageing, it is not an inherent 
part of the ageing process and medical, psychiatric, 
and psychosocial factors overshadow age as risk fac-
tors. There are numerous studies confirming that sleep 
disturbance in older adults is associated with increased 
morbidity and mortality and the evaluation and man-
agement of sleep disturbances in older adults is best 
approached as a multifactorial geriatric health condi-
tion, arising from impairments in multiple domains.
The most prevalent sleep disorders of today, such as 
insomnia or sleep-related breathing disorders, among 
which, Obstructive Sleep Apnea (OSA) is the most 
prevalent and important one, are strongly positively as-
sociated with age and make one of the most important 
risk factors for diminished quality of life, as well as in-
creased morbidity and mortality of the most prevalent 
diseases in general population, such as cardiovascular 
and glucose metabolism disorders, but also cancer, 
which has been published in many recent studies. Also, 
cognitive and psychomotor impairments are facilitated 
in the elderly in the presence of sleep disorders.
Increasing public awareness, improving and ex-
panding diagnostic and treatment capacities for sleep 
disorders, as well as education of sleep medicine ex-
perts, which was recently developed in the Republic of 
Croatia according to European guidelines, are the pri-
mary goals of up-to-date sleep medicine, one of the 
most prosperous medical discipline, which is going to 
be even more important in the future due to increased 
longevity in general population and strong links of 
sleep medicine and ageing.
Obstructive sleep apnea
Obstructive sleep apnea (OSA) increases with ad-
vancing age, with prevalence estimates differing de-
pending on the definition used. Using a definition of 
10 or more apneas and/or hypopneas per hour of sleep, 
OSA prevalence estimates in older adults may be as 
high as 70% in men and 56% in women. This is in con-
trast to prevalence estimates in the general adult popu-
lation of 15% in men and 5% in women. While it is 
more common, this condition frequently goes undiag-
nosed because the phenotype of OSA can look very 
different in older adults. After the age of 60, the preva-
lence of OSA is equivalent in males and females, obe-
sity is no longer a significant risk factor, and witnessed 
apneas and snoring are not as frequently reported. 
Older adults are also more likely to present with more 
sleep-related complaints, including daytime sleepiness 
and nocturia. Older adults are at risk for OSA for sev-
eral reasons. With aging there is loss of tissue elasticity 
as well as sarcopenic muscle wasting. There are also 
structural changes to the upper airway, including 
lengthening of soft palate and upper airway fat pad de-
position. These age-related changes increase the ten-
dency for oropharyngeal collapse. In addition, ventila-
tory control instability may predispose older adults to 
apneic events. The negative consequences of OSA in 
older adults include excessive daytime sleepiness, de-
creased quality of life, neurocognitive impairment, 
nocturia, and worsening of cardiovascular disease, 
particularly hypertension, heart failure and stroke. 
Diabetes mellitus and depression have also been found 
to be more common in older adults with OSA. The im-
pact of untreated OSA in older adults on mortality is 
not clear. However, older adults have similar adher-
ence rates to treatment, so there is no clear reason not 
to treat older adults with OSA. Recently there was a 
report of estimated risk for OSA in the Croatian popu-
lation published using the standardized international 
questionnaire named STOP (S-noring, T-iredness, O-
bserved apneas, elevated blood P-ressure), which was 
validated in Croatian language and proved to have 
high sensitivity and a reasonable specificity for detect-
ing people at risk for OSA (Dogas et al., 2018). In this 
report, on a rather large sample of almost 11,000 re-
spondents, there were high proportions of people at 
risk with strong and highly significant positive associ-
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ation with age (Figure 2). Also, men were at signifi-
cantly higher risk than women until elderly, were the 
numbers were similar.
sleep and ageing during  
the COVID-19 pandemics
Poor sleep is a risk factor for mental health, well-
being and susceptibility for infective diseases such as 
COVID-19 especially considering the crisis measures 
such as quarantine
Long-term home confinement due to an unprece-
dented global viral outbreak by COVID-19 of vague 
duration entails increased levels of stress and anxiety, 
disruption of established daytime and nighttime rou-
tines, as well as working schedules, causing deteriora-
tion of positive associations between home, relaxation 
and sleep (Altena et al., 2020). Given the commonness 
of stress-related sleep problems with possible adverse 
health consequences and the well-known bidirectional 
relation between emotional and behavioral reactivity 
and sleep quality, sleep disturbances during quaran-
tine may become an important issue for everyone. 
Furthermore, misalignment between behavioral and 
environmental cycles and environmental setting 
changes during isolation, including limited beneficial 
effects of natural daytime light exposure and artificial 
light suppression of the regular circadian rhythm, may 
impair circadian system organization and significantly 
influence sleep patterns, resulting together in an array 
of metabolic abnormalities (Altena et al., 2020). The 
rising pervasiveness of circadian rhythm and sleep dis-
ruptions during home confinement with increasing 
evidence of detrimental effects on health, emphasizes 
the importance of circadian system function and ad-
dressing sleep disturbances.
Sleep has been well-recognized as a marker of men-
tal health, especially in the elderly. Sleep problems 
were observed in most mental disorders and it has 
been proposed that sleep disturbances imply an arous-
al system imbalance likely representing a basic dimen-
sion of mental health, with polysomnographic find-
ings possibly playing a key role in psychiatric comor-
bidity processes. Also, it has been well established even 
in non-clinical populations that sleep quality is associ-
ated with mental health problems such as depression, 
anxiety and stress. Considering that elderly population 
is at particular risk for sleep disorders and mental 
health problems, the proposed association is of spe-
cific relevance in this population. Association of sleep 
and mental health has been extensively reported in el-
derly females, even after controlling for risk factors 
common to both. In addition, mental health is associ-
ated with physical health issues including general 
health status, activity limitations, and chronic health 
conditions in elderly females. The clinical and epide-
miologic evidence on the relationship between sleep 
and physical and mental outcomes highlight the rele-
vance of screening sleep issues in the general popula-
tion, and especially in vulnerable groups such as the 
elderly, those with multiple chronic diseases, sucha as 
sleep breathing disorders patients with cardiovascular 
and glucose metabolism comorbidities, but also stu-
dents as a partucularly sensitive group due to their 
specific sleep habits and risky environment such as 
quarantine and ongoing online education process.
Vulnerable population groups  
in COVID-19 pandemics
Present data point to the fact that COVID-19 infec-
tion is particularly serious in some population groups. 
Thus far, there is an international consensus that vul-
nerable populations for COVID-19 may include any-
one who is an older adult (65 years of age or older), 
anyone at risk due to an underlying medical condition 
Figure 2. Obstructive sleep 
apnea risk according to STOP 
questionnaire in different age 
groups (blue columns – male, 
red columns – female) in the 
Croatian population (Dogas 
et al., in prep).
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(such as cardiovascular disease, hypertension, diabe-
tes, chronic respiratory diseases, cancer), anyone at 
risk due to a compromised immune system from a 
medical condition or treatment and anyone with se-
vere obesity (BMI>40) (ECDC-Coronavirus disease 
2019 (COVID-19) in the EU/EEA and the UK – eighth 
update; WHO-Coronavirus disease 2019 (COVID-19) 
Situation Report-51). At present, there is no data that 
sleep-disordered breathing (especially Obstructive 
Sleep Apnea, OSA) increases the risk for contracting 
or developing more severe forms and outcomes of 
COVID-19. However, OSA is a condition character-
ized by many comorbidities including cardiovascular 
diseases, metabolic diseases (especially diabetes mel-
litus type 2; see Table 1 and Figure 3 for illustration of 
this overlap in the Croatian population; Dogas et al., 
2018) and respiratory diseases (Bonsignore et al., 
2019), all of which put the individual at a higher risk of 
COVID-19. Although it is considered a sleep disorder, 
OSA is also included in the International Classifica-
tion of Diseases list as a chronic respiratory disease 
(ICD-11, WHO). In OSA, the respiratory function is 
severely modified such that the episodes of partial or 
complete airway obstructions affect normal breathing 
patterns and gas exchange. Additionally, OSA is also 
more common in the older population (Young et al., 
2004), therefore it can be viewed as a superimposing 
factor to the initial risk stated for this specific popula-
tion. Finally, another risk factor for COVID-19 is obe-
sity and obese patients have been shown to have a 
higher incidence of OSA (Malhotra et al., 2002; Young 
et al., 2004), but are also more prone to developing 
other chronic diseases, especially the ones affecting 
the immune system. Having all of this in mind, this 
could make the individuals suffering from sleep-relat-
ed breathing disorders more susceptible to viral pneu-
monia-like diseases, such as COVID-19. Considering 
the high prevalence of sleep-disordered breathing, 
which is estimated in recent studies to be up to 25–
50% in the adult population, it is of major interest to 
assess the risk, prevalence and the outcomes of the 
COVID-19 disease caused by novel coronavirus SARS-
CoV-2 in this population.
OsA patients as a vulnerable group  
particulary sensitive to COVID-19
So far there is no data that OSA by itself increases 
risk of infection. For most OSA patients, a reduction 
in their quality of life is due to symptoms such as poor 
sleep quality, excessive daytime somnolence, and fa-
tigue with differences between gender, ages and na-
tions. Also, because of the known comorbidities such 
as hypertension, diabetes and obesity OSA patients are 
at higher risk in all age groups, especially in elderly, 
but also in many cases where OSA was not recognized 
and diagnosed before the COVID-19 infection. Also 
OSA patients might be more likely to develop compli-
cations of COVID-19 than other individuals because 
of an already compromised upper airway system, re-
petitive episodes of hypoxia and hypercapnia during 
the night, and also immune system. Therefore we 
might speculate whether OSA promotes negative out-
comes and more complications in patients diagnosed 
with COVID-19 especially if they have been diagnosed 
with comorbidities such as arterial hypertension, dia-
betes mellitus and obesity.
In patients who are diagnosed with moderate to se-
vere OSA, a continuous positive airway pressure 
(CPAP) device is a gold standard therapy and should 
be used permanently during sleep because without 
treatment, exacerbation of the disease will also include 
further weakening of the immune system, which make 
them more susceptible for infection. Precaution should 
be advised for patients who are at home in quarantine 
and regularly use CPAP devices. Usage of CPAP could 
spread the virus through the exhalation port, which al-
lows carbon dioxide to escape from the mask. This 
port also may release smaller virus-containing parti-
cles as an “aerosol,” which can remain suspended in 
the air for a few hours. However, patients with severe 
OSA should continue using CPAP while sleeping alone 
in a separate bedroom. So far, there is no studies show-
ing that using CPAP will cause more severe forms of 
Table 1. Proportion of subjects with Diabetes Mellitus 
type 2 (DM2) in the groups of respondents with and 
with no risk for OSA according to STOP questionnaire 
in different age groups; Number of subjects and 
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COVID-19, but we need more scientific research to 
provide evidence.
It should be emphasized that due to the lack of evi-
dence on COVID-19 infection severity and outcomes 
in OSA patients, both those treated at home or in a 
hospital settings with provided respiratory care (oxy-
gen and/or mechanical ventilation), especially in the 
vulnerable elderly populations during quarantine, this 
research question provides an innovative scientific re-
search interest.
Conclusions
Sleep Medicine is growing multidisciplinary field 
within the biomedicine and health. The most preva-
lent sleep disorders of today, such as insomnia or 
sleep-related breathing disorders are strongly positive-
ly associated with age and make one of the most im-
portant risk factors for diminished quality of life, as 
well as increased morbidity and mortality of the most 
prevalent diseases in general population, such as car-
diovascular and glucose metabolism disorders, but 
also cancer, which has been published in many recent 
studies. Also, cognitive and psychomotor impairments 
are facilitated in the elderly in the presence of sleep 
disorders.
One of the most notable findings regarding sleep in 
the elderly is the profound increase in inter-individual 
variability, which thus precludes generalizations such 
as those made for young adults.
The latest global developments empasized the fact 
that poor sleep is a risk factor for mental health, well-
being and susceptibility for infective diseases such as 
COVID-19 especially considering the crisis measures 
such as quarantine.
At present, there is no data that sleep-disordered 
breathing (especially OSA) increases the risk for con-
tracting or developing more severe forms and out-
comes of COVID-19. However, OSA is a condition 
characterized by many comorbidities including car-
diovascular diseases, respiratory diseases, metabolic 
diseases (especially diabetes mellitus type 2) and obe-
sity, all of which put the individual at a higher risk of 
COVID-19.
Increasing public awareness, improving and ex-
panding diagnostic and treatment capacities for sleep 
disorders, as well as education of sleep medicine ex-
perts, which was recently developed in the Republic of 
Croatia according to European guidelines, are the pri-
mary goals of up-to-date sleep medicine, one of the 
most prosperous medical discipline, which is going to 
be even more important in the future due to increased 
longevity in general population and strong links of 
sleep medicine and ageing.
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K-IV
Confronting the Dementia 
Pandemic: A World Economic 
Forum and Global CEO Initiative 
on Alzheimer’s Disease
Global Partnership to Speed Collaboration 
and Innovation
George Vradenburg
Convener, The Global CEO Initiative on Alzheimer’s Disease
Introduction:  
The Urgent need for Action
The world is confronting an emerging pandemic 
with absolutely no preparedness plan – one that threat-
ens to be larger, longer, more devastating, and more 
costly than COVID-19. The emerging pandemic: the 
expensive and lengthy chronic diseases of aging, espe-
cially dementia. The COVID-19 outbreak illustrates 
the dire consequences if health systems don’t prepare 
for dementia, which is already devastating older popu-
lations and impacting every aspect of society. It comes 
at a time when caregiving and working-age popula-
tions are shrinking, when national fiscal budgets need-
ed to support aging healthcare costs are under stress, 
and when the monetary policy mechanisms to drive 
economic growth in the face of a declining global 
workforce are exhausted. While COVID-19 is the cur-
rent public health priority, global leaders cannot afford 
to overlook dementia’s immense impacts – today and 
in the long-term. Already, more than 2.4 million peo-
ple die from dementia every year, and, in the U.S. 
alone, cumulative costs of care could exceed $20 tril-
lion from 2015 to 2050.(1,2) As the next pandemic, 
dementia is both inexorable and foreseeable.
The world needs a global preparedness plan for de-
mentia. On our current course, global dementia prev-
alence is projected to triple to 152 million families by 
2050, or close to 500 million affected people. In Eu-
rope, the number of people 60+ with dementia will 
grow by roughly 60% to more than 14 million by 2040.
(3,4) This surge in prevalence threatens to take an un-
sustainable toll – upending people’s lives and commu-
nities, straining healthcare systems, generating im-
mense costs, and draining workforces and economies.
We can change this trajectory. There is a growing 
consensus about the elements of a dementia prepared-
ness plan: early and systematic testing and detection, a 
standing global, industrial- strength, trial-ready sys-
tem for testing new therapies, public health interven-
tion plans to reduce peak prevalence, and a healthcare 
system ready and able to get the right intervention to 
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the right patient at the right time in disease progres-
sion. Sound familiar? What we largely did not have in 
place to address COVID-19, we need to put in place to 
address dementia.
This plan will require overcoming a number of chal-
lenges, from basic science to healthcare and public 
health system preparedness. Researchers need a better 
understanding of the heterogeneity of the causal path-
ways of dementia. Differential pathways require bio-
marker systems that can identify the differential popu-
lations for testing differential interventions. Current 
sporadic clinical testing systems must be built into ef-
ficient global trial platforms. Healthcare systems need 
accessible and affordable diagnostics to identify those 
at-risk for dementia and deliver precision interven-
tions to the right patient when they need them. Physi-
cians need training, tools, and incentives to provide 
early, accurate diagnoses. And the public needs the 
hope and confidence that there is something that can 
be done to prevent or treat cognitive decline – now.
To address the challenge of developing a global pre-
paredness plan for dementia, the World Economic 
Forum (WEF) and the Global CEO Initiative on Al-
zheimer’s Disease (CEOi) launched a new, global effort 
in Davos in January 2020: The Davos Alzheimer’s Col-
laborative (DAC). DAC is premised on the proposition 
that all nations and all sectors are in this together; that 
individual governments, as well as inter- governmen-
tal organizations, the pharmaceutical and biotech in-
dustries, leading researchers, and patient advocates, 
must come together to develop and execute a consen-
sus preparedness plan.
DAC will link current dementia efforts, scale suc-
cessful models, and create new initiatives – targeting 
four key areas:
•   Build a targeted global cohort of populations with 
or at risk of Alzheimer’s disease to drive discovery 
of precision intervention targets by focusing on 
research with populations that have genetic and 
genomic diversification.
•   Build a clear, coordinated, and comprehensive pre-
cision biomarker development process to accom-
pany the development of new precision targets.
•   Create a global platform to support global clinical 
trials capable of bringing new drugs to market at a 
faster rate.
•   Drive healthcare system preparedness to improve 
early detection and diagnosis, diagnostic and 
treatment delivery infrastructure, and patient af-
fordability of treatments.
We believe these steps are essential to making faster 
progress toward the discovery, testing, and delivery of 
precision interventions for dementia – and we believe 
Europe can and should take the lead. On behalf of 
DAC’s leadership and members, we look forward to 
discussing this urgent issue with European policymak-
ers, exploring opportunities for collaboration, and 
deepening our shared commitment to speeding de-
mentia innovation and preparedness.
Challenge: Global Population Aging  
and the Growing Impacts of Dementia
Rapid population aging presents a number of press-
ing challenges for every nation, for global economic 
growth, and for families around the world. Scientific 
and medical advances have brought us unprecedented 
longevity, raising average global life expectancy by 
more than 30 years in the past century.(5) There are 
now roughly one billion people over the age of 60 
globally, and this number is projected to increase to 2 
billion by mid-century.(6) Europe is at the forefront of 
this trend: there were more than 100 million people 
over the age of 65 in the EU-28 in 2018, or 20% of the 
population, and these numbers are projected to in-
crease to 149 million older people, or 29% of the popu-
lation, by 2050.(7)
While today’s aging and longevity are a modern 
miracle, they will also dramatically increase the bur-
den of age-related health conditions. We are not pre-
pared for this emerging pandemic, and dementia is the 
epicenter of the looming crisis. More than 50 million 
people live with dementia globally; projected to in-
crease to 152 million by 2050.(8) Europe is on the 
frontlines due its aging population. The number of 
people 60+ with dementia in the EU increased from 
5.9 million in 2000 to 9.1 million in 2018, and, if cur-
rent prevalence rates continue, this total is projected to 
grow by roughly 60% to 14.3 million in 2040.(9)
Without an urgent and coordinated response, this 
dramatic rise in prevalence will generate tremendous 
impacts on people, families, communities, and nation-
al healthcare systems, as well as on economic growth, 
workforce size and participation rates, and fiscal and 
monetary policy. Dementia is already the fifth leading 
cause of death worldwide, and, as of this paper, the 
only one of the top ten leading causes of death for 
which there is no truly effective treatment or cure.(10) 
The condition is responsible for roughly $1 trillion in 
annual costs, and this total is projected to double by 
2030.(11) Dementia also takes an enormous toll on 
families, who often provide unpaid, informal care for 
years or decades.
Now is the time for leaders to join together, across 
sectors and national boundaries, to take immediate, 
sustained, innovative action to develop and execute a 
dementia preparedness plan. We must accelerate re-
search progress to improve our understanding of de-
mentia and develop precision therapies and accompa-
nying biomarkers, while also drastically improving 
healthcare systems’ preparedness to effectively differ-
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entially diagnose dementia and deliver precision ther-
apeutics as they become available.
Context:  
The state of Dementia science and Policy
There is a growing consensus that meaningful thera-
peutic progress against dementia will require “shifting 
the science to the left” – understanding, detecting, di-
agnosing, and treating the condition in its earliest 
stages, including even before symptoms arise. This 
early intervention appears to be necessary for disease-
modifying therapies to maximize their effects over a 
long period, as indicated by promising recent clinical 
trial results for aducanumab and BAN 2401.(12,13) 
Therefore, “shifting to the left” offers a potential break-
through in an area where a new therapy has not been 
approved in the U.S. or Europe since 2003, and where 
more than 99% of clinical trials have not advanced to 
regulatory approval – the lowest for any therapeutic 
area.(14,15)
At the same time, there is also a growing scientific 
consensus that the causes and course of dementia var-
ies from individual to individual based on individual 
genetic, biological, and phenotypical variability and 
heterogeneity. This means that more diverse cohorts of 
individuals must be investigated to identify the “clus-
ters” of populations with sufficiently similar character-
istics that can be treated with the same intervention. 
That variability, in turn, requires accompanying bio-
markers or biomarker “clusters” to stratify populations 
for clinical research studies and for clinical diagnos-
tics, so that the healthcare system can “match” preci-
sion medicines to different subpopulations with or at 
risk of dementia.
As effective therapies are developed, regulators and 
payers will need to develop innovative methods to ap-
prove and reimburse for treatments that may slow, but 
not stop, disease progression and that may not show 
health system cost savings for years or decades – chal-
lenging current regulatory and payment models. 
Healthcare systems will need to improve rates of early 
detection and diagnosis, better characterize patient 
populations and people at-risk, and ensure necessary 
infrastructure to diagnose and deliver treatments. Ad-
ditionally, many dementia patients have one or more 
comorbid chronic conditions, further complicating ef-
forts to understand the disease, characterize patient 
populations, provide appropriate therapies, and mea-
sure the economic and health benefits of treatment.
Despite these challenges, growing momentum 
among policymakers, the private sector, international 
organizations, and dementia advocacy organizations 
points a way forward – and Europe can play a leader-
ship role in developing a transnational dementia pan-
demic preparedness plan. Europe has already led his-
toric efforts to address dementia, including the first 
national dementia plan in France in 2001 and the 
United Kingdom’s focus on dementia at the meeting 
of G8 Health Ministers in 2013.(16,17) Today, global 
leaders are stepping up their focus on dementia, as this 
topic was on center stage at the World Economic 
Forum in 2020 and spotlighted at the 2019 meeting of 
the G20 in Japan.(18)
These efforts provide hope, especially in light of re-
cent positive clinical trial results, a promising pipeline 
of new therapies, and a number of innovative demen-
tia initiatives in countries around the globe. Leading 
governments, companies, and international organiza-
tions are better positioned than ever before to change 
the trajectory of dementia and elevate dementia pre-
paredness on the global agenda. We cannot leave the 
lessons of COVID-19 unlearned as we confront the 
slow-burn pandemic of dementia.
The Global Initiative: The Collaboration  
to speed Alzheimer’s Innovation
In January 2020, the World Economic Forum (WEF) 
and the Global CEO Initiative on Alzheimer’s Disease 
(CEOi), launched the Davos Alzheimer’s Collabora-
tive (DAC), a multi-stakeholder, pre-competitive co-
alition designed to drive global scientific, business, 
policy, and financial coordination in dementia pre-
paredness.
DAC will build a coordinated strategy to link, scale, 
or initiate actions to diversify, accelerate, and deepen 
dementia preparedness efforts. Our long-term vision 
is to create a highly prioritized, well-resourced global 
Alzheimer’s research environment with an efficient 
path to market, supported by an engaged healthcare 
system.
DAC is uniquely positioned to achieve this vision 
because of members’ recognized global leadership, 
deep expertise, significant resources, and long-stand-
ing commitment. Members include leading govern-
ments, the leading and largest biopharmaceutical 
companies working in the dementia space, top inter-
national organizations, and influential organizations 
from the philanthropic sector. In addition, DAC is 
conducting ongoing discussions with a number of na-
tional governments to lead the policy element of the 
collaboration – including the United States, the Neth-
erlands, Japan, and Brazil – and we are eager to explore 
collaboration with other governments.
The leadership and members of DAC recognize that 
there are a wide range of important dementia efforts 
already underway around the globe. Therefore, DAC 
will embrace a “link, scale, create” approach – linking 
together relevant efforts to maximize their impact, 
identifying and scaling the best existing models, and 
creating new initiatives when no relevant efforts al-
20
LIJEČ VJESN 2020; godište 142; supplement 1; 3–25 Keynote speakers
ready exist. We believe this approach will enable great-
er efficiency and faster results.
Based on discussions with leaders and experts, DAC 
will target four key opportunities for innovation in de-
mentia: global cohort development; biomarker develop-
ment; global clinical trials; and healthcare system readi-
ness. We believe these four pillars offer the greatest 
promise to solve existing challenges in the space and 
catalyze rapid progress that makes a meaningful differ-
ence for people living with or at risk for dementia.
1. Build a targeted global cohort of populations 
with or at risk of Alzheimer’s disease to drive discov-
ery of precision intervention targets by focusing on 
research with populations that have genetic and ge-
nomic diversification.
Progress against dementia requires a comprehen-
sive, nuanced understanding of the condition. How-
ever, at the present time, researchers do not fully un-
derstand the disease’s heterogeneity. This lack of un-
derstanding limits the ability to identify new targets 
for drug development, as well as to execute precision 
medicine approaches to dementia.
DAC aims to address this challenge by creating a 
large prospective cohort – ideally, including 1 million 
people or more – with standardized approaches to 
deep biotyping and phenotyping. This effort will in-
clude the creation of Centers of Excellence to serve as 
pilot sites and leaders on innovation. To create the co-
hort, DAC will explore how to link relevant efforts that 
are already underway.
2. Build a clear, coordinated, and comprehensive 
precision biomarker development process to accom-
pany the development of new precision targets.
New targets for therapeutic interventions and preci-
sion medicine approaches require validated, standard-
ized biomarkers and diagnostics to improve early de-
tection and diagnosis, identify people for select treat-
ment, and better measure the efficacy of new therapies. 
However, existing biomarker development efforts are 
largely siloed, and biomarker data is rarely reproduc-
ible. Further, there is no clear pathway for the private 
sector to validate or qualify biomarkers, and there are 
limited commercial incentives to invest in this area.
DAC aims to address this challenge by building a 
clear pre-competitive pathway for the identification, 
standardization, validation, and reproducibility for bio-
marker development. The platform will standardize 
data sharing for biomarkers and enable the sharing of 
biological samples, thereby speeding research and treat-
ment delivery. The platform will also align stakeholders 
on high-value biomarkers and testing through current 
and future trials, further accelerating development.
3. Create a global platform to support global clini-
cal trials capable of bringing new drugs to market at 
a faster rate.
Progress against dementia requires faster and less 
costly clinical trials, thereby accelerating the develop-
ment of new therapies and attracting research invest-
ment. However, clinical trials are currently slow, labo-
rious, and expensive, often requiring years of effort 
from researchers, trial participants, and care partners, 
as well as immense investments from biopharmaceuti-
cal companies.
DAC aims to address this challenge by creating a 
global clinical trial support infrastructure. This will in-
clude a standing, trial-ready platform and an integrated 
network of high-performing institutional and private 
trial sites. The effort will also develop the capacity for 
adaptive and combination trials. These initiatives, to-
gether, will accelerate the delivery of new, more diverse 
therapies to market at greater speed and lower cost.
4. Drive healthcare system preparedness to im-
prove early detection and diagnosis, diagnostic and 
treatment delivery infrastructure, and patient afford-
ability of treatments.
DAC will engage national healthcare systems to im-
prove their preparedness for new Alzheimer’s thera-
pies, focusing on increasing testing and diagnosis, ex-
panding the availability of healthcare infrastructure 
and capacity, and ensuring access when new treat-
ments become available.
Progress against dementia requires dramatically im-
proving rates of early, accurate testing, detection, and 
diagnosis. Currently, testing, detection, and diagnosis 
is often late, slow, or inaccurate, if it’s made at all. In-
deed, 50% of patients with any form of dementia are 
not formally diagnosed, and, when diagnosis is made, 
it’s delayed by an average of 2–3 years after the onset of 
symptoms.(19,20) Further, 25% of patients clinically 
diagnosed with probable Alzheimer’s disease during 
their lifetime are found not to have Alzheimer’s pa-
thology at autopsy – raising questions about the accu-
racy of diagnosis.(21) There are a number of causes for 
these diagnostic challenges: providers lack sufficient 
training; the public is not educated about brain health, 
and patients rarely raise symptoms with providers; and 
there is a lack of simple, effective, and inexpensive di-
agnostics.
DAC aims to address this challenge through efforts 
to train physicians, educate the public, and spur the 
creation of diagnostics. DAC will increase the number 
of healthcare providers who are trained to detect and 
diagnose dementia and Alzheimer’s, as well as priori-
tize brain health and dementia prevention with the 
public and healthcare systems. DAC will also catalyze 
innovation in diagnostics and provide access to those 
diagnostics.
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Progress against dementia requires healthcare in-
frastructure to effectively and efficiently test for the 
condition and provide appropriate treatment. Howev-
er, healthcare systems currently lack critical infra-
structure for imaging, fluid, and genetic testing, infu-
sion sites for treatment, and sufficient training of the 
healthcare workforce. For example, genetic testing is 
not available in Germany, and Italy only provides re-
imbursement for infusion in a hospital by a specialist.
(22) The introduction of new treatments will place 
greater pressure on these gaps.
DAC aims to address this challenge by improving 
access to existing infrastructure and creating addition-
al system capacity. Working with national govern-
ments and healthcare systems, DAC may support the 
development of a “treatment-ready” population, drive 
access and acceptance of cerebrospinal fluid testing, 
and address access barriers for existing infrastructure.
Progress against dementia requires sufficient access 
to treatment for new therapies that enter the market. 
However, payers are concerned that new dementia ther-
apies will require high upfront costs, but without clear 
evidence, available when they enter the market, about 
whether and when a treatment will reduce downstream 
costs, improve health outcomes, and provide value. 
These concerns are particularly pressing for therapies 
that will need to be administered in pre- symptomatic 
or early-stage patients for a number of years.
DAC aims to address this challenge by increasing 
patient access, while reducing the risk to payers. Spe-
cifically, DAC will support innovative payment models 
and catalyze a post-approval platform to capture data 
on costs and outcomes in heterogenous populations. 
DAC will also support reimbursement for diagnostic 
testing and the availability of approved fluid diagnostic 
tools.
The Path forward:  
Building Cross-sector Collaboration  
and Leadership for Dementia Innovation
Global leaders must prioritize dementia innovation, 
if we are to build a healthy, prosperous, and productive 
future. While past dementia efforts have delivered im-
portant results, there is a pressing need to dramatically 
accelerate the pace and scale of global cross-sector col-
laboration, leadership, and innovation. This is the only 
way to achieve the advances that can make a meaning-
ful difference for communities, societies, and econo-
mies, as populations age in Europe and around the 
world.
DAC is eager to explore collaboration with Europe-
an governments to achieve this vision. National gov-
ernments will play a critical role as members of DAC 
by providing policy and financial support, co-conven-
ing stakeholders, and prioritizing and crafting innova-
tive dementia preparedness systems within their coun-
tries.
Together, we can seize the most important opportu-
nities for innovation and change the course of demen-
tia in our aging world.
For more information and to join our effort: 
Please contact Drew Holzapfel, Executive Director, The 
Global CEO Initiative on Alzheimer’s Disease at dholz-
apfel@highlanterngroup.com or +1.703.599.9617.
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John Middleton
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Immediate Past President, United Kingdom Faculty 
of Public Health Sir Richard Doll said he wanted ‘to 
die young as old as possible’. In his vision, the chance 
for more people to live to the Biblical 70 years was 
made greater by his discovery of cigarette smoking 
killing people prematurely, from lung cancer and heart 
disease and the opportunity presented to prevent all 
these diseases, by education. There was a post Second 
World War and post antibiotic revolution chimera, 
that infectious disease had been conquered and now 
we would apply all our efforts to the epidemics of non-
communicable disease. We would eradicate these too 
by rational investigation and removal of risks.
The reality in the United Kingdom, and perhaps for 
most countries is that this ideal is not being delivered. 
For many ’70 maybe the new 50’ but the benefits in 
improving life expectancy are not being experienced 
equally, within countries, or between countries and 
continents. Life expectancy may have been improving 
greatly in many countries. Healthy life expectancy is 
improving less, and inequalities in healthy life expec-
tancy are widening. Sir Michael Marmot’s graph of life 
expectancy and healthy life expectancy in over 200 
neighbourhoods of England shows a gap of over 10 
years in life expectancy, but a gap of over 20 years in 
healthy life expectancy. This gap represents the time a 
person will live with one or more long term condi-
tions. (1)
I used to be Director of Public Health in Sandwell in 
the post-industrial West Midlands of England. There, 
a poor working-class man in West Bromwich may 
think it is normal to have chest pain at 45, or to be 
breathless climbing a flight of stairs. Many more will 
live with the daily diet and treatment rituals of obesity-
induced type 2 diabetes. Obesity is the norm in the 
West Midlands, with over two thirds of the adult pop-
ulation obese or overweight. Lifetimes of poor and in-
secure employment, poor education opportunities and 
life without hope, leave people prone to the ravages of 
multinational companies peddling highly processed 
high-fat high-sugar foods, alcohol, tobacco and gam-
bling. The multi-national companies employed the 
‘merchants of doubt’ to question Sir Richard’s rational 
evidence of tobacco as the cause of lung cancer. The 
‘Big’ purveyors of non-communicable disease, Big 
Food, Big Tobacco, Big Alcohol, Big Gambling, Big 
Fossil fuel, have all adopted their merchants of doubt, 
Figure 2. Life expectancy at birth by neighbourhood 
deprivation percentiles, 2009–13, England
a) Males
b) Females
Source: Office for National Statistics (ONS) and Department for Work and Pensions (14) (15) (16)
Note: Each dot represents life expectancy (LE) or disability-free life expectancy (DFLE) of a 
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are still alive and thriving on human misery. Years of 
austerity since the 2008 financial crash, have seen a 
double assault on the health and livelihoods of people 
in the poorer areas of the United Kingdom. Health has 
been directly damaged, with the resultant diseases of 
despair- alcoholism, addictions, poor mental health 
and suicide, accidents and violence. Alongside this the 
services many have come to rely on to help them in 
these times of need, have been cruelly and cynically 
cut. I reviewed the extent of the damage to United 
Kingdom public health in my President’s valedictory 
address to the members of the United Kingdom Fac-
ulty of Public Health in June 2019. (https://better-
healthforall.org/2019/07/30/past-presidents-end-of-
term-report-part-2-the-health-of-the-public/) It has 
also been graphically set out by Marmot and colleagues 
this year. (1)
A public health approach to healthy ageing requires 
good data to describe the position of older people are 
living in and to propose solutions and evaluate inter-
ventions. It requires thorough knowledge of the major 
causes of ill health, dependency and inequality- in 
poor housing, inadequate income, environmental 
problems, poor and unrewarding work and poor 
chances for a fulfilling life and leisure, unsatisfactory 
family and social support networks. And it requires 
healthy public policy interventions to address these.
A public health approach requires improvement of 
environments in which older people live- involving 
town planners and engineers in moves towards ‘de-
mentia friendly cities’, and ‘accessible cities’, and for 
communities which enable active travel and participa-
tion throughout life. Strong community involvement 
is required, and inter-generational activities. Citizen-
led activities to promote healthier ageing are vital; a 
central tenet of health promotion is that health and 
care needs cannot be met solely through expert and 
professional provision- most care is delivered by fam-
ily and community carers, so too must preventive in-
terventions. Across the social divide, people live in-
creasingly sedentary leading older people to become 
frail and dependent before their time. Resources de-
veloped by Sir Muir Gray in the United Kingdom seek 
to help people stay active, physically and mentally, as 
they get older, developing the concept of “optimal age-
ing’ https://www.livelongerbetter.net. Individuals can 
be given the tools for personal support and for main-
taining their own health- support from peers, self help 
groups, ‘expert patients’ can be important in helping 
people to maintain their independence and assert their 
personalities and their dignity and respect as human 
beings. Social prescribing has come into vogue- health 
professionals able to ‘prescribe’ a fitness class or a 
cooking class. This risk professionalising everyday ac-
tivities, but it also enables prescriptions to be for more 
appropriate care. Many schemes recognise the need 
for housing repairs on prescription and welfare rights, 
rather than just ‘lifestyle’ prescriptions. Some of the 
tools for personal support are in the fields of new tech-
nology. Video conferencing has been propelled to rou-
tine and everyday by the current pandemic. Older 
people who may not have been computer literate are 
picking up the controls. Micro-technologies also en-
able more activities of daily living to be supported; the 
costs of mass production and modular production for 
aids and adaptations is coming down and enabling 
more people with disabilities, to not be handicapped, 
and so remain independent.
And we need health and social care services which 
are reoriented towards effective interventions, and 
which are responsive to personal needs. Within health 
systems, public health approaches are important – 
some of these can be considered the ‘epidemiology of 
health care’. ‘Value-based health’ also as advocated by 
Muir Gray, and as presented in a European Union re-
port last year (2), require all working in public health 
and health care to re-evaluate effective health service 
interventions and eliminate wasteful practices and the 
least effective clinical and care measures. The OECD 
report on “Wasteful Spending in Health” (2017) pre-
sented alarming data on inappropriate care and wasted 
resources with estimations ranging from a conservative 
10% up to 34% of expenditures. Less wasteful care can 
reduce costs, but also reduce health harms, iatrogenic 
disease including side effects of medications, hospital 
acquired infections and blood clotting disorders, acute 
anxiety and disorientation, and so on. Appropriate care 
requires much more active involvement of individual 
patients and their carers. Less intervention may be bet-
ter care. ‘Adding life to years’ becomes more important 
than merely ‘adding years to life’. Quality of life be-
comes of paramount importance. But even where high 
technology and heroic intervention is justified, pa-
tients, carers and families, must be informed and be 
able to play an active part in the decision making, in 
what has come to be called ‘the co-production of health’. 
Even in end of life care, a public health approach, as 
exemplified by the compassionate communities model, 
is important; as advocated by Professor Alan Kellahear, 
death cannot be professionalised and managed exclu-
sively by health and care services; families and com-
munities are the most affected and need to be given the 
tools and resources to be confident in talking about 
death and being supportive for people in the last period 
of life, and those around them.
All of these areas of intervention require a public 
health system and public health professionals to be in-
clusive and working in partnership, with health and 
care services, but also with many other agencies, com-
munities and disciplines. The public health profession-
al does not have exclusive and comprehensive knowl-
edge of everything that can be done to protect and 
improve the health of the public. We need to under-
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stand other languages- and speak them well enough- 
town planner, transport manager, housing specialist, 
economist, educationist, communications expert, 
community activist, public policy analyst and increas-
ingly, we need to add climate scientist, ecologist, theo-
logian, international lawyer and political scientist. All 
of these and more are vital to the health of the people 
and planet (3)
And we need to embrace law, ethics, rights and val-
ues. We need to reaffirm our values. We need to restate 
our belief in equality, in the rights of individuals to 
health and to access to health and social care which is 
universally available. We must value all individuals 
equally. We must avoid drifting into the uncaring sen-
timents, which do not value or recognise the rights 
and autonomy or even become a cynical expression of 
political philosophy, such some have expressed in the 
current COVID-19 pandemic. ‘It’s only killing the el-
derly’, or, ‘those with underlying conditions’; invoking 
herd immunity in which some will ‘taking it one chin’ 
for others to survive.
The COVID-19 pandemic has highlighted weak-
nesses in my country, of social care, which is run by 
private companies and individuals, which is un-
planned, unresilient, and dependent on an army of 
over 1.5 million low paid care workers who are mainly 
from European Union countries and minority ethnic 
groups. Some English local health organisations have 
been reluctant to support privately run care homes 
with NHS expertise, in such crucial areas as infection 
control, medicines management, falls prevention and 
tissue viability and pressure sores prevention. There is 
a growing call for a national health and social care sys-
tem in England. Other countries may face similar 
problems- while others, notably Scandinavian coun-
tries, have organised older persons care more securely.
There is clearly much to be done, in our respective 
countries, and internationally, to ensure we all have the 
maximum opportunity to live fulfilling lives, free of ill 
health for as long as possible, and protected by safety net 
coverage of health and care services when we need 
them. The COVID-19 pandemic has uncovered weak-
nesses in services in some countries and offered glimps-
es of how health might be improved for the future. Be-
yond COVID-19, we will need to redouble our efforts to 
prevent climate breakdown, address major health dam-
aging trade problems, curb the obscene powers of mul-
tinational corporations which damage our health and 
address global problems of intolerance, epidemic resort 
to violence and organised armed conflict.
There is an emergency planning cliché, that ‘we 
should hope for the best and plan for the worst’. The best 
we should hope for, is to die young as old as possible, 
in a peaceful , more equal world, but we should plan 
for the worst- develop our health and care systems and 
our preventive services, to make our hope a reality.
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Biomedical Engineering, Artificial 
Intelligence and Internet of Things 
for Healthy Ageing
Leandro Pecchia
Applied Biomedical Signal Processing and Intelligent eHealth Lab,  
University of Warwick, UK
In 2014, the World Health Organization (WHO) 
stated that more ‘trained and qualified biomedical engi-
neering professionals are required to design, evaluate, 
regulate, maintain and manage Medical Devices, and 
train on their safe use in health systems around the 
world’. In 2015, the European Institutions engaged in a 
wide discussion with the European (i.e., European Al-
liance for Medical and Biological Engineering and Sci-
ence, EAMBES) and the global (i.e., The International 
Federation of Medical and Biological Engineering, 
IFMBE) community of biomedical engineering (BME) 
practitioners and scholars. The results of this discus-
sion resulted in a report published in the European 
Journal in April 2015 (2015/C 291/07) stating that 
‘Biomedical Engineering is not simply a subset of mod-
ern medicine. Modern medicine predominantly secures 
important advances through the use of the products of 
biomedical engineering’. In 2018, the European Com-
mission included for the first time “Biomedical Engi-
neering” in the European Skills, Competences, Quali-
fications and Occupations (ESCO) database.
This growing attention is probably due to the dizzy-
ing growth of the main product of biomedical engineer-
ing: medical devices. In fact, Europe is leading the 
growth of the medical device sector, accounting for the 
30% of the global market, employing about 1 million 
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of workers in this area and leading by large the innova-
tion in this field (e.g., number of papers, patents and 
research grants in this area). The market of medical 
devices will probably become one of the main drivers 
of the EU economy over the next years. A proxy for 
this forecast is the number of patent applications sub-
mitted per year. In fact, while the yearly number of 
patent applications per pharma and biotechnologies is 
still doing very well (about 6,000 novel patent applica-
tions per year), the number of patents for medical 
technologies is doing twice better, with over 12,000 
novel patent applications in 2016 (1).
The fast evolution and diffusion of available and af-
fordable medical devices is contributing to shape the 
future of medicine focus and practice. In fact, medi-
cine is going to be more focused towards the wellbeing 
(not just health) of citizens, focusing more and more 
on primary prevention and lifestyle management. 
After hundreds of years, medical practice is expanding 
the remit of medical care from hospitals towards the 
monitoring and correction of citizens’ health trajecto-
ries in real-life.
The fast development of artificial intelligence (AI), 
internet of things (IoT), telecommunications (e.g., 5G) 
and the convergence of these technologies into the 
medical device domain is offering novel and unprece-
dented opportunities to collect and use huge amount 
of data (a.k.a., big-data) for advancing medical knowl-
edge and improving patient management, especially in 
later life.
In this fascinating scenario, this talk will illustrate 
how AI, IoT and big-data are going to be used in the 
forthcoming years in order to make healthcare inter-
ventions more affordable, sustainable, effective and safe.
This talk will present a series of pilot studies in 
which these innovative technologies are used for fos-
tering active and healthy ageing and to improve the 
prevention, diagnosis, treatment and management of 
chronic conditions.
Finally, this keynote will rise the attention on cur-
rent gaps, which are hindering the adoption of these 
promising technologies in everyday clinical practice 
and citizen life, and what policy-makers can do, in 
order to foster this unprecedented opportunity to im-
prove the quality of life and the independency of se-
nior citizens. Among other challenges, policy-makers 
will have to drive the change towards the adoption of 
novel assessment and reimbursement strategies for 
technologies improving primary prevention.
R e f e R e n C e
1. Pecchia L, Pallikarakis N, Magjarevic R, Iadanza E. Health 
Technology Assessment and Biomedical Engineering: Global 
trends, gaps and opportunities. Med Eng Phys. 2019;72:19–26.
